Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Joan Oloff is Making Fashion More Functional

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In a fashion landscape dominated by established brands, it can be difficult for a start-up to stand out. By providing customers with clothing and accessories that look great but can also be worn on the job, new brands are able to break through this barrier.

Few designers exemplify this innovative spirit as much as Joan Oloff. A podiatrist by training, Joan set out to make the first line of orthopedically correct high heels. After seeing the issues that traditional high heels cause in her patients, Joan knew there had to be a way to design beautiful shoes that wouldn’t negatively impact the health of the wearer’s feet down the road.

The challenge was taking elements already common in athletic and walking shoes, like offloading pressure points, incorporating shock-absorption and providing proper support, and finding a way to implement these same features in heels. Over the course of four years, Joan worked with designers and manufacturers, in both Los Angeles and Italy, to make her line of shoes fit her standards. It was difficult. The manufacturers didn’t want to do things her way. But she pushed ahead.

“If I’m not going to be a game-changer, if I’m not going to disrupt the way high heels are made, there’s no point for me to do this,” Joan said in an interview with the San Francisco Chronicle.

Her perseverance paid off and today, Joan Oloff’s shoes have built-in arch support, cushioning material in the ball of the foot and a lower heel pitch, all of which allow the entire foot to comfortably share the body’s weight. Perhaps the most impressive aspect of her line is simply the diversity of options. Made by hand, the latest collection has everything from sandals to knee-high boots. The beauty of the line, combined with the comfort of the shoes, have garnered Joan a loyal following. One surgeon in Santa Fe owns ten pairs of the shoes as they allow her to work without discomfort be it in her office, visiting patients or even conducting an hours-long surgical procedure.

While her customers all praise her shoes, Joan also has proof to back up her claims that she makes healthy heels. Using CurveBeam’s revolutionary pedCAT technology, Joan is able to show weight-bearing CT scans of her shoes in action. When compared side-by-side with the same scans of someone wearing standard heels, it is obvious that Joan’s shoes provide evenly distributed support and stable positioning while other shoes have toe crimping and no arch support, creating a painful experience for the wearer.

Just like Joan Oloff, CurveBeam is dedicated to changing the game. By creating innovative 3D scanning technology that provides a complete view of a patient’s lower extremities, the pedCAT has given podiatrists, physical therapists, and others the ability to give their patients the proper treatment they need. Learn more about pedCAT here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512